Sagawa K, Gouhara R, Sudo T, Tatsumi E, Peiper S C, Minowada J
Department of Immunology, Kurume University School of Medicine, Japan.
Kurume Med J. 1995;42(3):177-85. doi: 10.2739/kurumemedj.42.177.
In an attempt to identify the antigens expressed on human myeloid leukemia cells, two murine monoclonal antibodies (mAb) designated as MCS-1 (isotype; IgG3) and MCS-2 (IgG1) were raised. MCS-1 reacted with peripheral blood granulocytes, but not with monocytes, whereas MCS-2 reacted with both granulocytes and monocytes. The incidence of MCS-1 and MCS-2 reactivity with the cells from a total of 121 patients with various type of leukemias was as follows: 25/46 (54%) and 39/47 (83%) in acute myeloblastic leukemia and acute monoblastic leukemia, 8/16 and 16/16 in chronic myeloid leukemia in blastic crisis (CML-BC) of myeloid type, 0/7 and 2/7 in CML-BC of lymphoid type, 0/26 and 2/32 in acute lymphoblastic leukemia (ALL), 7/7 and 7/7 in chronic phase of CML, respectively. Two cases of MCS-2 positive ALL had a Philadelphia chromosome marker (Ph1). In contrast, neither MCS-1 nor MCS-2 reacted with lymphocytes or any of leukemic and non-leukemic lymphoid cell lines tested. These results indicate that MCS-1 and MCS-2 mAb recognized two different differentiation antigens expressed on granulocytes and monocytes. These mAb would be useful reagents to determine differentiation antigens on the cells in granulocyte and monocyte lineage.
为了鉴定人类髓系白血病细胞上表达的抗原，制备了两种鼠单克隆抗体（mAb），分别命名为MCS-1（同种型：IgG3）和MCS-2（IgG1）。MCS-1与外周血粒细胞反应，但不与单核细胞反应，而MCS-2与粒细胞和单核细胞均反应。MCS-1和MCS-2与总共121例不同类型白血病患者的细胞反应的发生率如下：急性髓细胞性白血病和急性单核细胞性白血病中分别为25/46（54%）和39/47（83%），髓系类型的慢性髓性白血病急变期（CML-BC）中为8/16和16/16，淋巴系类型的CML-BC中为0/7和2/7，急性淋巴细胞白血病（ALL）中为0/26和2/32，慢性期CML中为7/7和7/7。两例MCS-2阳性ALL患者有费城染色体标记（Ph1）。相反，MCS-1和MCS-2均不与淋巴细胞或任何测试的白血病和非白血病淋巴系细胞系反应。这些结果表明，MCS-1和MCS-2 mAb识别粒细胞和单核细胞上表达的两种不同分化抗原。这些mAb将是确定粒细胞和单核细胞系细胞上分化抗原的有用试剂。
